Cancer Disease-Oriented-Drug Development Examples
DOI:
https://doi.org/10.17140/CSMMOJ-7-132Keywords:
Cancer, Neoplasms, Chemotherapy, Antitumor agents, Drug developmentAbstract
The history of cancer medical treatments goes up to 1908 with the use of arsenic in this disease. An intermediate milestone was
the discovery, in 1943, of an amazing tumor response using nitrogen mustard in a patient with a radio-resistant lymphoma. Chemotherapy
really born with this achievement, and a plethora of antitumor agent’s came to age after 1948 till nowadays. Here, some
examples of recent disease-oriented drug development approaches are presented and analyzed, as well as present limitations and
challenges raised by each one.
References
DeVita VJr., Lawrence T, Rosenberg S. Cancer, Principles & Prac-tice of Oncology. 11th ed. PA, USA: Wolters Kluver; 2019: 297-311.
Lietman CD, Johnson ML, McCormick F, Lindsay CR. More to the RAS story: KRAS G12C inhibition, resistance mechanisms and moving beyond KRAS G12C. Am Soc Clin Oncol Educ Book. 2022; 42: 1-13. doi: 10.1200/EDBK_351333
Stalnecker CA, Der CJ. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Sci Signal. 2020; 13: eeay6013. doi: 10.1126/scisignal.aay6013
Schmid P, Cortes J, Dent R, et al. Event-free survival with Pem-brolizumab in early triple-negative breast cancer. N Eng J Med. 2022; 386: 556-567. doi: 10.1056/NEJMoa2112651
Cortés–Guiral D, Hübner M, Alyami M, et al. Primary and met-astatic peritoneal surface malignancies. Nat Rev Dis Prim. 2021; 7: 91. doi: 10.1038/s41572-021-00326-6
No authors listed. On-target BTK mutations promote resis-tance to noncovalent BTK inhibitors. Cancer Discov. 2022; 12(5): 1179. doi: 10.1158/2159-8290.CD-RW2022-041 Opinion | Volume 7 | Number 1|
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
